Trial Profile
A Single-arm, Phase Ⅱ Clinical Trial of Anlotinib Hydrochloride Combined With Irinotecan or Docetaxel for Second Line Treatment of Nonsensitive Relapsed Small-cell Lung Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Jul 2023
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary) ; Docetaxel (Primary) ; Irinotecan (Primary)
- Indications Meningeal carcinomatosis; Small cell lung cancer
- Focus Therapeutic Use
- 06 Jun 2023 Results (As of Jan 31, 2023, n=39) presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 27 Jul 2021 New trial record
- 08 Jun 2021 Results (n=21; data cutoff: 8 Feb 2021) presented at the 57th Annual Meeting of the American Society of Clinical Oncology